Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenström's Macroglobulinemia
Status:
Recruiting
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of the BCL2 inhibitor BGB-11417 in
participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) in 3 cohorts.